New York- and Alabama-based IN8bio is leveraging gamma-delta (γδ ... suggest leveraging γδ T cells’ natural ability to target malignancy-induced NK group 2D (NKG2D) stress-associated ...

T cell engagers are an exciting area of immunotherapy that remains in the early innings of development. We believe gamma-delta T cells offer unique properties, including tissue residence, phagocytosis ...

Adicet Bio, Inc. (NASDAQ:ACET), a clinical-stage biopharmaceutical company with a market capitalization of $65.5 million, focuses on developing engineered gamma-delta T cell therapies. The company ...

IN8bio, Inc NEW YORK, March 31, 2025 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company developing innovative gamma-delta T cell therapies for cancer and ...